The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.
We are pleased to present our new newsletter and outreach initiative to deliver succinct and frequent information about our company.
Feel free to send us your feedback by clicking on the thumb emoji in the email footer, or by emailing us at newsletter@lanternpharma.com.
Happy reading!
Clinical Trial Preparations Update: The Harmonic trial is on schedule for a Summer 2022 launch. Lantern is finalizing revisions of the protocol amendment to the IND with the FDA - these are anticipated to be completed by the end of June. Lantern is currently in the process of contracting clinical trial sites for patient enrollment and is targeting a total of 15-20 sites to reach enrollment of 90 patients in the US.
In a previous Phase 3 clinical trial, when LP-300 was administered with chemotherapy in a subset of never-smoker non-small cell lung cancer (NSCLC) patients, there was an increase in overall and 2-year patient survival by 91% and 125%, respectively, compared to chemotherapy alone. Additionally, LP-300 has been well tolerated in over 1,000 people.
Why it matters: Lung cancer is the #1 cause of cancer deaths in the US and never-smokers with NSCLC are estimated to account for 15-20% of these deaths. NSCLC in never-smokers can be genetically different from lung cancer in smokers and patients may benefit from new therapies like LP-300 with chemotherapy.
New Promising Preclinical Results for LP-284: Lantern conducted a study implanting mice with mantle cell lymphoma (MCL) xenografts and treating them with either LP-284 at 2 mg/kg or 4mg/kg, Bortezomib at 1 mg/kg, Ibrutinib at 50mg/kg, or Saline as a control.
This study is still ongoing and final results will be available in the coming months.
Why it matters: MCL is an aggressive subtype of B-cell non-Hodgkins Lymphoma that is typically diagnosed in advanced stages and has a low 2-5 year median patient survival.
The positive preclinical results for LP-284, in vitro and in vivo, suggest that LP-284 has the potential to fill the treatment void for MCL patients, who often lack effective treatment options.
Dr. Maccecchini has over 30 years of biopharmaceutical experience in the development of novel therapies for Alzheimer's, Parkinson's, and other neurodegenerative diseases. She is the founder of Annovis Bio. (Nasdaq: ANVS), a company dedicated to treating neurodegenerative conditions, and has served as its President, Chief Executive Officer, and Director since 2008.
Dr. Maccecchini was elected along with five existing Directors at Lantern's Annual Meeting of Stockholders held on June 8, 2022.
Lantern hosted a KOL webinar on GBM and LP-184 for the potential treatment of GBM in May, which was Brain Tumor Awareness Month. The webinar featured two leading experts for the
treatment of glioblastoma - John Laterra, MD, PhD and Matthias Holdhoff, MD, PhD from The Johns Hopkins University School of Medicine - as well as Lantern’s Chief Scientific Officer, Kishor Bhatia, PhD.
Why it matters: Every year, 13,000 people in the US are diagnosed with GBM and patients have a low 15-month median survival with treatment. In preclinical studies, LP-184 has shown nanomolar potency against GBM in vitro and in vivo, and crosses the blood brain barrier. LP- 184 has the potential to become a new line of therapy for GBM where there is an urgent and unmet clinical need.
If you missed the webinar, watch the replay here:
https://us06web.zoom.us/rec/share/cwxZFeZMxdXlL4sIDbY6ek_URTb9w11wYiPiy-ABnSW-TWvNXBB9XXvYmJVHowZB.0XQyNfs-hYrY5xkQ?
startTime=1653580571000
This week, Panna Sharma, Lantern’s CEO & President, spoke at the LD Micro Invitational XII in Westlake Village, CA on June 7th, 2022. Find more info here: https://ldinv12.mysequire.com
Panna will be speaking at the MedInvest Oncology Investor Conference on June 28th and 29th, 2022 in midtown Manhattan. Register here: https://www.medinvestconferences.com/register
Additionally, Panna will be speaking at the World Orphan Drug Congress USA 2022 in Boston, MA on July 11-13, 2022.
Register here: https://secure.terrapinn.com/V5/step1.aspx?E=10568&p=1
Follow Lantern Pharma on Twitter and LinkedIn for all of the latest updates.
This newsletter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events, our plans to advance the development of our drug candidates and antibody drug conjugate program, or our future financial performance. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this newsletter represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.